LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
How many calories should you eat on GLP-1 medications? This is a crucial question for individuals prescribed glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) or liraglutide (Victoza, Saxenda) in the UK. These medications significantly reduce appetite and promote early satiety, naturally lowering calorie intake. However, consuming too few calories can lead to nutritional deficiencies, muscle loss, and fatigue, whilst excessive intake may limit therapeutic benefits. There is no universal calorie target—requirements vary based on your metabolic rate, activity level, treatment goals, and overall health. Understanding appropriate calorie intake on GLP-1 therapy is essential for safe, effective weight management and metabolic health.
Quick Answer: There is no single universal calorie target for GLP-1 medications; most adults require a moderate deficit of approximately 600 calories below total daily energy expenditure, typically 1,400–1,900 calories daily, individualised to your metabolic rate, activity level, and treatment goals.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications increasingly prescribed in the UK for type 2 diabetes management and, in specific cases, for weight management in adults with obesity. For diabetes management, these medications include semaglutide (Ozempic), liraglutide (Victoza), and dulaglutide (Trulicity). For weight management, only semaglutide (Wegovy) and liraglutide (Saxenda) are specifically licensed in the UK, with access typically through specialist weight management services according to NICE criteria.
These medications work by mimicking the action of the naturally occurring GLP-1 hormone, which is released from the intestine after eating.
The mechanism of action involves several physiological effects that directly influence appetite and calorie intake. GLP-1 receptor agonists slow gastric emptying, meaning food remains in the stomach longer, promoting feelings of fullness. They also act on appetite centres in the brain, particularly the hypothalamus, to reduce hunger signals and increase satiety. Additionally, these medications enhance insulin secretion in a glucose-dependent manner and suppress glucagon release, helping to regulate blood glucose levels.
When starting GLP-1 treatment, many patients experience a significant reduction in appetite and early satiety—feeling full after consuming smaller portions. This naturally leads to reduced calorie intake, which contributes to weight loss. However, this appetite suppression raises an important clinical question: what is the appropriate calorie intake to maintain health whilst on these medications?
Understanding your calorie requirements on GLP-1 therapy is essential for several reasons. Consuming too few calories can lead to nutritional deficiencies, muscle loss, fatigue, and other adverse health effects. Conversely, consuming excessive calories may limit the therapeutic benefits of the medication. The balance requires individualised assessment, taking into account your baseline metabolic rate, activity level, treatment goals, and overall health status.
There is no single universal calorie target for all individuals taking GLP-1 medications, as requirements vary considerably based on multiple factors. However, clinical guidance and nutritional science provide helpful frameworks for determining appropriate intake.
For most adults on GLP-1 therapy for weight management, NICE guidelines recommend a moderate calorie deficit of approximately 600 calories below your total daily energy expenditure (TDEE). This approach typically results in a safe, sustainable weight loss of approximately 0.5 to 1 kg per week. The NHS 12-week weight loss plan often uses frameworks of around 1,400 calories daily for women and 1,900 calories for men, though these should be individualised based on your specific needs.
It is crucial to note that very low calorie diets (VLCDs) of less than 800 calories per day should only be followed under medical supervision within a structured, multicomponent weight management programme, as advised by NICE. Unsupervised very low calorie intake can lead to nutritional inadequacies, gallstone formation, electrolyte imbalances, and loss of lean muscle mass.
For individuals using GLP-1 medications primarily for diabetes management rather than weight loss, calorie requirements may be higher, focusing on weight maintenance rather than reduction. In these cases, consuming calories at or near your TDEE is appropriate, with emphasis on blood glucose control through balanced macronutrient distribution. If you are taking insulin or sulfonylureas alongside GLP-1 therapy, you should monitor your blood glucose closely and discuss medication adjustments with your healthcare provider to prevent hypoglycaemia as your food intake changes.
Clinical trials of semaglutide and other GLP-1 agonists have not prescribed specific calorie targets but rather encouraged reduced-calorie diets alongside the medication. The STEP trials, for instance, combined semaglutide with lifestyle intervention including dietary counselling aimed at a 500-600 calorie deficit. This approach acknowledges that the medication itself facilitates calorie reduction through appetite suppression, making adherence to lower-calorie intake more achievable.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Individual calorie requirements on GLP-1 therapy depend on numerous physiological and lifestyle factors that must be considered for personalised nutritional planning.
Basal metabolic rate (BMR) forms the foundation of your calorie needs, representing the energy required for basic physiological functions at rest. BMR is influenced by age, sex, height, weight, and body composition. Individuals with greater muscle mass have higher metabolic rates. As you lose weight on GLP-1 treatment, your BMR naturally decreases, meaning calorie requirements should be periodically reassessed.
Physical activity level significantly impacts total energy expenditure. Sedentary individuals require fewer calories than those who exercise regularly or have physically demanding occupations. The UK Chief Medical Officers recommend at least 150 minutes of moderate-intensity or 75 minutes of vigorous activity weekly for adults, plus muscle-strengthening activities on at least two days per week. Maintaining physical activity during GLP-1 treatment helps preserve lean muscle mass during weight loss.
Treatment goals also determine appropriate calorie intake. Those prescribed GLP-1 medications for weight management through NHS specialist services (typically individuals with BMI ≥35 kg/m² or ≥30 kg/m² with comorbidities, according to NICE criteria) may target a larger calorie deficit than those using these medications primarily for glycaemic control with modest weight management.
Existing medical conditions influence nutritional needs. Individuals with diabetes must balance calorie reduction with blood glucose stability. If you take insulin or sulfonylureas alongside GLP-1 therapy, you may need medication adjustments to prevent hypoglycaemia as your food intake decreases. Those with cardiovascular disease, kidney disease, or other chronic conditions may have specific dietary requirements that affect calorie distribution and total intake.
Medication dosage and duration can affect appetite suppression intensity. Higher doses typically produce more pronounced satiety effects, potentially making it more challenging to meet minimum calorie requirements. As your body adjusts to the medication over several weeks, appetite may partially return, necessitating ongoing dietary monitoring.
Beyond total calorie intake, nutritional quality is paramount for individuals on GLP-1 therapy. The reduced appetite and smaller portion sizes make every calorie count towards meeting essential nutrient requirements.
Protein intake deserves particular attention during GLP-1 treatment. The UK Reference Nutrient Intake (RNI) for protein is 0.75 grams per kilogram of body weight daily, but during weight loss, a higher intake may help preserve lean muscle mass. Under dietetic guidance, an intake of approximately 1.0 to 1.2 grams per kilogram of body weight daily may be appropriate, particularly for older adults or those losing weight. This translates to approximately 75 to 100 grams daily for many adults. Prioritise high-quality protein sources including lean meats, fish, eggs, dairy products, legumes, and plant-based alternatives. Distributing protein across meals, rather than concentrating it in one sitting, optimises muscle protein synthesis.
Fibre-rich foods should feature prominently in your diet, supporting digestive health and providing sustained satiety. The Scientific Advisory Committee on Nutrition (SACN) recommends 30 grams of fibre daily from sources such as vegetables, fruits, whole grains, and pulses. Given that GLP-1 medications slow gastric emptying, adequate fibre and hydration help prevent constipation, a common side effect.
Micronutrient adequacy becomes more challenging with reduced food intake. Focus on nutrient-dense foods that provide vitamins and minerals relative to their calorie content. The NHS Eatwell Guide provides a helpful framework for balanced nutrition. Include colourful vegetables and fruits, fortified foods, and consider a multivitamin supplement if dietary intake is restricted, particularly ensuring adequate vitamin B12, vitamin D, calcium, and iron.
Hydration is essential, as reduced food intake means less fluid from food sources. Aim for 6 to 8 glasses (approximately 1.5 to 2 litres) of water daily, adjusting for activity level and climate. Adequate hydration supports kidney function, helps manage potential side effects, and can help distinguish between hunger and thirst.
Meal timing and frequency should align with your appetite patterns on GLP-1 therapy. Some individuals find smaller, more frequent meals easier to manage and better tolerated, whilst others prefer three structured meals. Listen to your body's hunger and fullness cues whilst ensuring you meet minimum nutritional requirements.
Several nutritional pitfalls commonly occur when individuals begin GLP-1 therapy, potentially compromising health outcomes or treatment efficacy.
Consuming too few calories represents perhaps the most significant concern. The pronounced appetite suppression can make it surprisingly easy to under-eat, particularly in the initial weeks of treatment or following dose escalations. Some patients report consuming fewer than 800 calories daily without realising the potential consequences. Intakes below 800 calories per day constitute very low calorie diets (VLCDs) and should only be followed under medical supervision. Inadequate calorie intake may lead to fatigue, dizziness, hair loss, possible menstrual irregularities, mood changes, and nutritional deficiencies. It may also trigger adaptive metabolic responses that slow weight loss over time and increase the likelihood of weight regain after treatment cessation.
Inadequate protein consumption is another frequent error. When appetite is suppressed, individuals often gravitate towards easily consumed foods, which may be carbohydrate-heavy and protein-poor. Insufficient protein intake during weight loss accelerates loss of lean muscle mass, which can reduce metabolic rate, impair physical function, and compromise long-term weight management.
Neglecting nutrient density in favour of calorie counting alone can result in micronutrient deficiencies. Filling limited calorie allowances with processed foods, even if they fit calorie targets, fails to provide essential vitamins, minerals, and phytonutrients necessary for optimal health.
Irregular eating patterns sometimes develop when appetite is significantly reduced. Skipping meals entirely or going extended periods without eating can lead to blood glucose fluctuations, particularly concerning for individuals with diabetes. For those taking insulin or sulfonylureas, this may increase hypoglycaemia risk, requiring medication review. Irregular eating may also make meeting nutritional requirements more difficult.
Failing to adjust calorie intake as weight decreases is another common oversight. As body weight reduces, so do calorie requirements. What constituted an appropriate deficit initially may need modification several months into treatment to continue progress safely.
Ignoring side effects that affect nutrition, such as nausea, vomiting, or food aversions, can compound nutritional inadequacy. These symptoms should be addressed proactively through dietary modifications and, if persistent, medical consultation. If you experience suspected side effects from GLP-1 medications, you can report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).
Professional nutritional guidance is valuable for most individuals starting GLP-1 therapy and essential in certain circumstances.
Ideally, all patients beginning GLP-1 treatment should receive dietary counselling from a registered dietitian or appropriately trained healthcare professional. NICE guidance on obesity management emphasises the importance of multicomponent interventions that include dietary, physical activity, and behavioural components alongside pharmacological treatment. For weight management, GLP-1 medications are typically initiated within specialist weight management services according to NICE criteria. A dietitian can assess your individual requirements, develop a personalised eating plan, and provide ongoing support to optimise outcomes.
Specific situations warrant urgent professional dietary consultation:
Unintentional excessive weight loss—losing more than 1 kg weekly consistently, or experiencing rapid weight loss that feels uncontrolled
Inability to meet minimum calorie requirements due to severe appetite suppression, nausea, or other side effects
Signs of nutritional deficiency, including unusual fatigue, weakness, hair loss, brittle nails, frequent infections, or poor wound healing
Pre-existing eating disorders or disordered eating patterns, as GLP-1 medications may complicate these conditions
Complex medical conditions such as chronic kidney disease, liver disease, or malabsorption disorders requiring specialised dietary management
Pregnancy or breastfeeding—GLP-1 medications should not be used during pregnancy; if you become pregnant whilst on treatment, stop the medication and seek immediate medical and nutritional review
Contact your GP urgently if you experience:
Severe, persistent abdominal pain (with or without vomiting) which could indicate pancreatitis
Upper-right abdominal pain, fever or jaundice which may suggest gallbladder disease
Persistent nausea or vomiting preventing adequate nutrition
Signs of dehydration (dark urine, dizziness, reduced urination)
Unexplained symptoms such as jaundice, severe fatigue, or mood changes
For people with diabetes: hypoglycaemia (low blood sugar) symptoms when taking insulin or sulfonylureas alongside GLP-1 therapy
Regular monitoring throughout GLP-1 treatment should include periodic assessment of weight, body composition where possible, nutritional intake, and relevant blood markers. This collaborative approach between you, your prescribing clinician, and nutrition professionals ensures that calorie intake supports both your treatment goals and overall health, maximising the benefits of GLP-1 therapy whilst minimising potential risks.
Very low calorie diets below 800 calories daily should only be followed under medical supervision within a structured weight management programme, as unsupervised restriction can lead to nutritional deficiencies, muscle loss, gallstones, and electrolyte imbalances.
Yes, as your body weight decreases, your basal metabolic rate and total calorie requirements naturally reduce, so calorie intake should be periodically reassessed with your healthcare provider to ensure continued safe and effective weight management.
Protein intake is particularly important, with 1.0–1.2 grams per kilogram body weight daily recommended to preserve lean muscle mass. Adequate fibre (30 grams daily), hydration, and micronutrients including vitamin B12, vitamin D, calcium, and iron are also essential with reduced food intake.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
